A comprehensive view of Ocugen Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Ocugen announces FDA has declined to issue Emergency Use Authorization for pediatric use of COVAXIN to prevent COVID-19 in individuals aged two to 18
Published: March 07, 2022 by CE Noticias Financieras
Ocugen announces the FDA has lifted clinical hold on submission of its new COVID-19 vaccine candidate COVAXIN; vaccine is a whole-virion inactivated COVID-19, rather than mRNA technology
Published: February 23, 2022 by GlobeNewswire
Ocugen submits request to FDA to start Phase 3 clinical trial of the COVAXIN COVID-19 vaccine candidate; product is a whole-virion inactivated COVID-19 made with manufacturing processes used for polio vaccines
Published: October 27, 2021 by GlobeNewswire

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count